Cuneo Antonio, Bigoni Renato, Rigolin Gian Matteo, Roberti Maria Grazia, Bardi Antonella, Cavazzini Francesco, Milani Raffaella, Minotto Claudia, Tieghi Alessia, Della Porta Matteo, Agostini Paola, Tammiso Elisa, Negrini Massimo, Castoldi Gianluigi
Institute of Hematology, University of Ferrara, via Savonarola 9, 44100 Ferrara, Italy.
Haematologica. 2002 Jan;87(1):44-51.
Chromosome 11q22.3-23.1 deletions involving the ataxia-teleangiectasia mutated (ATM) locus (11q-/ATM+/-) are detected at diagnosis in 10-20% of cases of B-cell chronic lymphocytic leukemia (CLL) and are associated with a relatively aggressive disease. The aim of this study was to ascertain whether 11q-/ATM+/- may appear late during the course of the disease and to analyze its possible correlation with disease evolution.
Eighty-two patients with CLL and related disorders, i.e. CLL/PL and prolymphocytic leukemia (PLL), without 11q- at diagnosis were sequentially ascertained at 1-2 year intervals by conventional cytogenetic analysis (CCA) and fluorescence in situ hybridization (FISH), using an ATM-specific probe.
Eight patients acquired a submicroscopic 11q deletion 13-43 months after diagnosis: the diagnosis at presentation was CLL in 3 cases, CLL/PL in 3 cases and PLL in 2 cases. A 13q14 deletion preceded the development of 11q- in four patients; additional aberrations included +12 (three cases), 17p13 deletion and 6q21 deletion (one case each). The acquisition of the 11q deletion was more frequently found in those patients presenting with CLL/PL and PLL than typical CLL (p=0.0016) and with splenomegaly (p=0.003). Follow-up data showed that karyotype evolution (p=0.009) and cytological transformation (p<0.001) were associated with the acquisition of this cytogenetic lesion. The variables predicting for a shorter survival in this series included the 11q deletion (p=0.03), along with other classical clinicobiological parameters (performance status, advanced stage, splenomegaly, elevated serum beta2 microglobulin and lactate dehydrogenase levels.
a) Submicroscopic 11q deletion involving the ATM locus may, in some instances, represent a secondary change in CLL, CLL/P and PLL, suggesting that sequential FISH analyses are necessary to detect this chromosome anomaly in some patients; b) the acquisition of 11q-/ATM deletion may play a role in determining cytological transformation and disease progression of CLL and related disorders.
在B细胞慢性淋巴细胞白血病(CLL)病例中,10% - 20%在诊断时可检测到涉及共济失调毛细血管扩张突变(ATM)基因座的11号染色体q22.3 - 23.1缺失(11q - /ATM+/-),且与相对侵袭性疾病相关。本研究旨在确定11q - /ATM+/-是否可能在疾病进程中晚期出现,并分析其与疾病进展的可能相关性。
82例诊断时无11q - 的CLL及相关疾病患者,即CLL/PL和幼淋巴细胞白血病(PLL)患者,通过常规细胞遗传学分析(CCA)和荧光原位杂交(FISH),使用ATM特异性探针,每隔1 - 2年进行一次序贯检测。
8例患者在诊断后13 - 43个月出现亚显微11号染色体缺失:初诊时3例为CLL,3例为CLL/PL,2例为PLL。4例患者在11q - 出现之前先有13q14缺失;其他异常包括 +12(3例)、17p13缺失和6q21缺失(各1例)。11号染色体缺失在CLL/PL和PLL患者中比典型CLL患者更常见(p = 0.0016),且与脾肿大有关(p = 0.003)。随访数据显示,核型演变(p = 0.009)和细胞学转化(p < 0.001)与这种细胞遗传学病变的出现相关。本系列中预测生存期较短的变量包括11号染色体缺失(p = 0.03),以及其他经典的临床生物学参数(体能状态、晚期、脾肿大、血清β2微球蛋白和乳酸脱氢酶水平升高)。
a)涉及ATM基因座的亚显微11号染色体缺失在某些情况下可能是CLL、CLL/P和PLL的继发改变,提示对某些患者进行序贯FISH分析对于检测这种染色体异常是必要的;b)11q - /ATM缺失的出现可能在决定CLL及相关疾病的细胞学转化和疾病进展中起作用。